News Release

Chicago, IL, June 3, 2013and Osaka, Japan, June 4, 2013 – Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from a Phase 1 study evaluating the safety, tolerability, and maximum tolerated dose (MTD) of MLN9708, the first investigational oral proteasome inhibitor in clinical trials. The study evaluated once a week oral dosing of single agent MLN9708 in patients with relapsed and/or refractory multiple myeloma (MM). These data were reported in an oral presentation during the annual meeting of the American Society of Clinical Oncology (ASCO), held May 31st to June 4th in Chicago, Illinois.

“Single agent MLN9708 showed promising responses in heavily pretreated patients with relapsed and/or refractory multiple myeloma. Responses were observed regardless of prior therapies, which included various proteasome inhibitors and immunomodulatory agents,” said Karen Ferrante, M.D., Head of the Takeda Oncology Therapeutic Area Unit. “These data further support the study of once a week oral MLN9708 in the three on-going global Phase 3 TOURMALINE trials of MLN9708.”

Weekly MLN9708, an investigational oral proteasome inhibitor, in relapsed/refractory multiple myeloma: Results from a phase I study after full enrollment(Abstract #8514)This ongoing study evaluated MLN9708 in 60 MM patients who had received two or more prior therapies. The primary objectives were to determine the safety, tolerability and MTD of once a week MLN9708. Results from the dose-escalation and expansion cohorts presented by Shaji Kumar, M.D., included:

Patients aged 18 years or older received MLN9708 on days 1, 8, and 15 of 28-day cycles. In the dose-escalation phase, patients were required to have ≥2 prior therapies (including bortezomib, thalidomide/lenalidomide, and corticosteroids).

About MLN9708

MLN9708 is an investigational oral, proteasome inhibitor, which is being studied in multiple myeloma and other malignancies. It is the first oral proteasome inhibitor to enter clinical trials. Three global Phase 3 trials are on-going; TOURMALINE-MM1, investigating MLN9708 in combination with lenalidomide and dexamethasone in relapsed and/or refractory MM, TOURMALINE-MM2, investigating MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed MM who are not eligible for transplantation, and TOURMALINE-AL1, investigating MLN9708 plus dexamethasone in patients with relapsed or refractory light chain amyloidosis (AL). For additional information on the ongoing Phase 3 studies please visit www.tourmalinetrialal1.com and www.tourmalinetrialmm1.com and http://clinicaltrials.gov/show/NCT01850524.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

You Are Leaving Takeda Oncology

You are now leaving takedaoncology.com. Links to sites outside of takedaoncology.com are provided as a resource to the viewer. takedaoncology.com accepts no responsibility for the linked sites that takedaoncology.com has no control over.

Interacting with Takeda Oncology on Social Media

Definition of Social Media

Takeda Oncology recognizes the importance of social media channels in the communication space. However, in embracing these channels, we aim to engage responsibly. Below, we have outlined our current active channels as well our terms and guidelines for interacting with us on these channels. Current channels in which Takeda Oncology participates:

Other services may be added. Check back occasionally to see all of the channels we support.

These channels were created and are managed by Takeda Oncology. Their purpose is to educate the public about our company, mission, values as well as the diseases we aspire to cure and the populations we serve. The content posted by Takeda Oncology is for informational and educational purposes only and is NOT intended to be a substitute for professional medical advice.

Mentions, comments, likes, favorites and retweets are welcomed! However, please note, the pharmaceutical industry is a highly regulated one and as a result we may not be allowed to respond to "@mentions" and replies that:

Please note that accounts that Takeda Oncology follows/interacts with or accounts that follow/interact with us on our various channels are not an indication of Takeda Oncology's endorsement of these accounts or the content they produce. Additionally, favorites, likes, comments and/or retweets do not indicate endorsement.

Takeda Oncology may provide links or references to other websites as part of its social content. We claim no responsibility for the accuracy or content of such other sites and shall not be liable for any damages or injury arising from that content.

Please do not use these channels to report adverse events or medical side effects. If you believe that you have experienced any medical side effects or reactions from a Takeda Oncology product you should consult your physician, pharmacist or other healthcare professional immediately. You can also report these to us directly by calling us here: 1-877-TAKEDA7.

We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues. In scenarios when Takeda Oncology cannot post or respond to your comment, we will send a private message to you explaining why.

Thank you for your interest in connecting with us on social media — we look forward to hearing from you and sharing more about our work in the fight against cancer.

DISCLAIMER

Takeda Oncology does not endorse any user or associated products and services of any social media user that interacts with our profiles. Takeda Oncology may link to an external website for interest or convenience. Takeda Oncology claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Takeda Oncology reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.